Cite

HARVARD Citation

    Hodi, F. et al. (n.d.). LBA44Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). Annals of oncology. p. . [Online]. 
  
Back to record